Treatment of Dermatofibrosarcoma Protuberans in Patients 10 Years and Younger
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 7
- 试验地点
- 2
- 主要终点
- Patient developing recurrence of a biopsy-proven dermatofibrosarcoma protuberans at one year.
研究概览
简要总结
The purpose of this proposed study is to assess effectiveness of MOHS micrographic surgery as a form of treatment for dermatofibrosarcoma protuberans in patients who are 10 years of age or younger through review of the patients at Mayo Clinic treated from 1988-2017, and to explore the challenges that providers face which may prevent them performing this potentially superior treatment. This study will provide a comparison of outcomes and recurrence rates in pediatric patients treated by MOHS versus traditional excision.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 10 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Patient developing recurrence of a biopsy-proven dermatofibrosarcoma protuberans at one year.
时间窗: Recurrence will be assessed at 1 year.
Developing an additional dermatofibrosarcoma protuberans at any location, but particularly noting local recurrence (defined as being within or contiguous to the field of the previous excision.
次要结局
- All cause mortality(All cause mortality will be assessed at 1 year, and then annually thereafter for up to 10 years. All patients will have at least one year of follow up.)
- Patient developing recurrence of a biopsy-proven dermatofibrosarcoma protuberans at two years.(Recurrence will be assessed at 2 years. (Not all patients will have a full two years of follow up))
- Mortality related to dermatofibrosarcoma protuberans(Mortality related to dermatofibrosarcoma protuberans will be assessed at 1 year, and then annually thereafter for up to 10 years. All patients will have at least one year of follow up.)
- Morbidity secondary to surgical procedure(Morbidity secondary to surgical procedure will be assessed at 1 year, and then annually thereafter for up to 10 years. All patients will have at least one year of follow up.)
- Patient developing recurrence of a biopsy-proven dermatofibrosarcoma protuberans at five years.(Recurrence will be assessed at 5 years. (Not all patients will have a full five years of follow up))
研究者
Randall K. Roenigk
Professor of Dermatology
Mayo Clinic